It should be emphasized that evidence supporting HER2-ICI and PI3K-AKT-mTOR-ICI combinations in breast cancer is derived predominantly from phase I/II studies and small single-arm cohorts, and no large randomized trial has yet established a clear survival advantage of these regimens over current standard-of-care treatments. Here, ERBB2 is linked to breast cancer.